Form 4: Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden Sells Shares Under 10b5-1 Trading Plan

Jeffrey Leiden, Executive Chairman of Vertex Pharmaceuticals, sold 3,784 shares of common stock at $499 per share on August 30, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 30, 2024, Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, sold 3,784 shares of the company's common stock.
• The sale was executed at a price of $499 per share.
• Following the transaction, Leiden directly owns 9,994 shares of Vertex Pharmaceuticals' common stock.
• He also indirectly owns 440 shares through a 401(k) plan.
• The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was established on May 10, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Sales by executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates